Keyphrases
Acute Leukemia
6%
Acute Lymphoblastic Leukemia
26%
Aggressive B-cell Lymphoma
7%
Allogeneic
6%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
10%
American Society
9%
Anti-CD19 chimeric Antigen Receptor T Cells
21%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
25%
B-cell Malignancies
13%
Blinatumomab
9%
CART19
9%
CD19
23%
CD19 CAR T Cells
11%
CD19 chimeric Antigen Receptor T Cells
23%
CD19+
6%
CD28
11%
Cell Infusion
7%
Cell Therapy
10%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Chimeric Antigen Receptor T-cell Therapy
40%
Clinical Response
9%
Clinical Utilization
6%
Complete Remission
9%
Complete Response
7%
Confidence Interval
9%
Cytokine Release Syndrome
8%
Engraftment
8%
European Society
6%
Event-free Survival
11%
Expert Opinion
6%
Glioblastoma
7%
Graft-versus-host Disease (GvHD)
11%
Haploidentical Hematopoietic Stem Cell Transplantation
13%
Hematological Malignancies
6%
Hematopoietic Stem Cell Transplantation
8%
Hematopoietic Stem Cells
6%
HLA-matched Donor
7%
Improved Outcomes
11%
Large B-cell Lymphoma
10%
Leukemia
17%
Marrow Transplantation
6%
Older Adults
16%
Overall Survival
18%
Pediatric
11%
Pediatric Patients
8%
Point-of-care
12%
Relapsed or Refractory
20%
Relapsed or Refractory Acute Myeloid Leukemia
17%
T Cells
17%
Tisagenlecleucel
9%
Medicine and Dentistry
Acute B-Cell Lymphoblastic Leukemia
20%
Acute Leukemia
6%
Acute Lymphoblastic Leukemia
40%
Allogeneic Hematopoietic Stem Cell Transplantation
8%
B Cell
21%
B-Cell Lymphoma
10%
Blinatumomab
5%
Cancer
10%
CD19 Antigen
5%
Cell Therapy
12%
Chimeric Antigen Receptor
32%
Chimeric Antigen Receptor T-Cell
91%
Chimeric Antigen Receptor T-Cell Immunotherapy
34%
Clinical Trial
6%
Cyclophosphamide
5%
Cytokine Release Syndrome
7%
Disease
8%
Event Free Survival
10%
Graft Versus Host Reaction
10%
Haploidentical Hematopoietic Stem Cell Transplantation
6%
Hematopoietic Stem Cell
5%
Hematopoietic Stem Cell Transplantation
7%
Immunotherapy
10%
Infusion
12%
Large-Cell Lymphoma
11%
Leukapheresis
6%
Leukemia
13%
Mitochondrial DNA
6%
Neoplasm
5%
Non-Hodgkin Lymphoma
9%
Overall Survival
15%
Pediatrics
15%
Pediatrics Patient
6%
Precursor
7%
Salvage Therapy
7%
T Cell
28%
T Lymphocyte Receptor
5%
Transplantation
8%
Immunology and Microbiology
B Cell
31%
Blinatumomab
6%
CD19
48%
CD19 Antigen
5%
CD28
5%
Chimeric Antigen Receptor
28%
Chimeric Antigen Receptor T-Cell
52%
Chimeric Antigen Receptor T-Cell Therapy
19%
Conditioning
8%
Cyclophosphamide
8%
Engraftment
6%
Event Free Survival
10%
Graft-Versus-Host Disease
11%
Haploidentical Hematopoietic Stem Cell Transplantation
12%
Hematopoietic Cell
6%
Immunotherapy
10%
Myeloid
6%
Overall Survival
10%
Precursor
7%
T Cell
30%
T Cell Receptor
9%
Transplant Procedure
8%